Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

Biosimilars: Still Waiting for Promise to Materialize

Larry Beresford  |  January 17, 2018

During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:2017 ACR/ARHP Annual MeetingACR/ARHP Annual MeetingBiologics & BiosimilarsBiosimilarsdrug pricingDrug Updatesinterchangeability

Biosimilars Great Debate: To Switch or Not?

Susan Bernstein  |  November 17, 2017

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

Filed under:Biologics/DMARDsEducation & TrainingMeeting Reports Tagged with:2017 ACR/ARHP Annual MeetingBiologicsBiosimilarsJonathan KayRheumatic DiseaseRoy Fleischmann

CMS Implements Part B Modifiers for Biosimilars

From the College  |  September 20, 2017

With the advent of biosimilars to the marketplace, the Centers for Medicare and Medicaid Services (CMS) now requires modifiers to identify the manufacturer of a biosimilar/biological product on Part B claims. Modifiers were put in place to provide the CMS with the necessary data needed to track claims payments, as well as the ability to…

Filed under:Biologics/DMARDsFrom the College Tagged with:BiosimilarsCenters for Medicare & Medicaid Services (CMS)InflectraPart B modifiers for biosimilarsRenflexis

2 Biosimilars Make Their Way Toward the European Market

Michele B. Kaufman, PharmD, BCGP  |  July 17, 2017

Two biosimilar treatments, Rixathon and Imraldi, are moving closer to market release in Europe for the treatment of rheumatic and other diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiosimilarsEuropean Medicines AgencyPsoriasisrituximabRixathon

U.K. Competition Watchdog Accuses Merck of Obstructing Biosimilars

Ben Hirschler  |  May 23, 2017

LONDON (Reuters)—Britain’s competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade (infliximab) that it said was designed to restrict competition from so-called biosimilar copies. The Competition and Markets Authority (CMA) says it had provisionally found the U.S. company’s European unit, Merck Sharp & Dohme (MSD), had abused…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsinfliximabInternationalLegalMerck & CoRemicadeREMICADE (infliximab)U.K.

As Biosimilars Hit, EU Pharma Warns against Blanket Prescribing

Reuters Staff  |  March 10, 2017

LONDON (Reuters)—European drugmakers, faced with increasing competition from cut-price copies of complex biotech drugs, cautioned doctors on Thursday to take care when switching patients from an established product to biosimilar version. The complex nature of biological medicines, which are made inside living cells, means copies can never be exactly the same as the original. But…

Filed under:Biologics/DMARDs Tagged with:biosimilar cancer drugBiosimilarsCancerTruxima

Biosimilars to Raise Unique Questions

Vanessa Caceres  |  February 16, 2017

Rheumatologists are accustomed to educating patients about medications, but biologic medications—and now biosimilars—require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. The first FDA-approved biosimilar to become…

Filed under:Biologics/DMARDs Tagged with:BiologicsBiosimilarsFDAInflectraRemicade

Syda Productions/shutterstock.com

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

Vanessa Caceres  |  February 15, 2017

Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:Association of Rheumatology Professionals (ARP)BiologicsDrugspatient carePractice ManagementQualityrheumatologistrheumatologySafetytherapyTreatment

Step Therapy, Biosimilars among ACR’s 2017 State-Level Priorities

Kelly Tyrrell  |  January 17, 2017

Opportunities and challenges will continue to face the rheumatology community in 2017. In response to these challenges, the ACR has outlined its federal– and state-level legislative and regulatory healthcare priorities for the year. Howard Blumstein, MD, chair of the ACR Affiliate Society Council, says that achieving at least some of these priorities at the state…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Biosimilarsprior authorizationspecialty tieringstep therapy

Potential Benefits, Pitfalls of Biosimilars Reviewed at EULAR 2016

Thomas R. Collins  |  September 8, 2016

LONDON—The availability of a bio­similar form of infliximab has dramatically increased the number of Norwegians taking one form or another of the drug, an expert on biosimilars said in a debate-style session at the Annual Congress of the European League Against Rheumatism (EULAR 2016). The expanded uptake of Remicade (infliximab) and its biosimilar, Remsima (international…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:benefitsBiosimilarsdrug updateEULAREuropean League Against Rheumatismpatient carepitfallResearchrheumatology

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 31
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences